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Luz Saúde, S.A. is one of the largest companies within the Portuguese health sector. 
Offering differentiated services, the company achieved considerable growth, in spite of 
the ongoing economic crisis. Given its structure and desirability to foreign investors, it 
would eventually be acquired almost entirely in 2014. 
This study aims to determine the intrinsic value of Luz Saúde, S.A.’s shares, through a 
detailed analysis of the group's operating performance and external environment. The 
evaluation was based on the method of discounted cash flows, which according to the 
literature review, is the best methodology for evaluating Luz Saúde. This evaluation 
suggests that the company’s share price on 12/31/2014 was underestimated, i.e. the 
share was rated below its intrinsic value of 3.80 euros, thus presenting a potential of 
appreciation of 22, 15%, resulting in a recommendation to buy for interested investors. 
 
Keywords: Evaluation of Companies; Free Cash Flow to Firm; Enterprise Value, Equity 
Value, Adjusted Present Value, Health Sector, Luz Saúde. 
  






Luz Saúde, S.A. é uma das maiores empresas da área da saúde em Portugal. Com um 
serviço diferenciado a empresa tem conseguido um crescimento considerável mesmo 
em períodos económicos adversos. Com uma estrutura e área de negócio bastante 
apetecível a investidores estrangeiros, acabou por ser adquirida quase na totalidade 
em 2014. 
Este trabalho tem como objetivo determinar o valor intrínseco das ações da Luz Saúde, 
através de uma análise detalhada do desempenho operacional do grupo e de seu 
ambiente externo. A avaliação foi baseada no método dos fluxos de caixa descontados, 
que de acordo com o estabelecido na revisão da literatura constitui a melhor 
metodologia para avaliar a Luz Saúde. 
Com esta avaliação, foi possível concluir que o valor da ação da Luz Saúde em 
31/12/2014 encontra-se subvalorizada, ou seja, foram cotados abaixo do seu valor 
intrínseco 3,80 euros, apresentando assim um potencial de valorização de 22,15%, foi 
dada uma recomendação de compra aos investidores interessados. 
Keywords: Evaluation of Companies; Free Cash Flow to Firm; Enterprise Value, Equity 
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1.1) Background  
The financial crisis that hit Portugal between 2010 and 2014, following the global 
financial crisis of 2007 - 2008, coupled with the euro zone’s public debt crisis, affected 
every economic activity in Portugal. With a high structural deficit, the Portuguese 
government was forced to reduce investments. One of the sectors where this 
disinvestment was particularly noticeable was the public health sector, with a decrease 
of 16% between 2010 and 2014. The private health sector, however, made an 
investment of 0.41% in the same period. 
Plot 1 - Investment Flutuation in Health 
 
 
Regarding relative weight, the disinvestment in the public sector and stabilization in 
the private sector caused the disparity between public investment in public and private 
health to eventually be reduced. 
2010 2011 2012 2013 2014
Private Health Sector 0,00% 1,79% 0,43% -4,17% 2,50%
Public Health Sector 0,00% -8,22% -8,76% -0,24% 0,68%














Plot 2 - Distribution of Investment in Health 
 
 
The private health sector was one of the few sectors showing great potential in the 
Portuguese market, even within the financial crisis context. 
The main objective of this project is to evaluate Luz Saúde, S.A., determining the 
intrinsic value of its shares on 12/31/2014. Evaluating a company requires a detailed 
analytic approach, considering every variable that affects its value, including external -  
macroeconomic or industry factors -, and internal variables - financial indicators, 
business segments, strategies and growth prospects. This is a very important analysis, 
contributing to the efficiency of the financial market, and providing new information 
and recommendations to investors on whether to buy or sell the company’s shares. 
Luz Saúde, S.A. is one of the largest companies in the Portuguese private health sector, 
competing directly with the market’s leading groups: the Mello Group and Lusiadas 
Group. 
1.2) Project Structure 
This work is structurally divided in six sections: 
2010 2011 2012 2013 2014
Private Health Sector 30% 32% 34% 33% 34%















 The first section corresponds to the literature review, where every methods of 
assessment will be referred, but only the discounted cash flows method will be 
analyzed, summarizing the leading academic publications on the subject. This review 
will make it easier to understand the method’s application and identify the most 
appropriate methodology for evaluating Luz Saúde, S.A.; 
 The second section contains a detailed analysis of Luz Saúde S.A. in the last five 
years, particularly regarding its objectives, strategies and operational and market 
performance; 
 The third section covers the sector’s and macroeconomic 
framework/background, presenting each direct competitor; 
 The fourth section comprises a strategic analysis of the company using two 
important management tools: SWOT and Porter's 5 Forces analyses. This strategic 
analysis is the result of a compilation of conclusions drawn from the analyses carried 
out in the second and third sections; 
 The fifth section details the evaluation of Luz Saúde S.A. Initially, the main 
assumptions will be defined, and then the evaluation method - Free Cash Flow To Firm 
(FCFF) - will be applied; 
 Finally, in the last section, the assessment results will be presented and 
analyzed; the main objective will be to compare the intrinsic value of the shares to 
their market value, in order to subsequently give recommendations to future 
investors. 
  




2) Literature Review 
 
2.1) Company Evaluation 
A company evaluation is the process of determining the value of a commercial, 
industrial, service or investment organization, in order to pursue an economic activity, 
Neves (2002). According to Damodaran (2006), evaluations are pivotal in finances, 
being used in different business contexts, specifically in portfolio management in 
merge and acquisitions (M&A), and in Corporate Finance. In Corporate Finance, the 
best way to add value to a company is investigated changing their investment 
decisions, financing and dividend policy, Damodaran (2006). In portfolio management, 
the importance of an evaluation depends on the investor's characteristics; for a 
passive profile investor, the evaluation has a minor role, whereas to an active profile 
investor, evaluation is key, Damodaran (2002). Finally, in M&A, an evaluation of the 
same company can result in different values. The buyer’s assessment might not 
respond normally to the seller’s or even to other buyers’ assessments due to different 
perceptions of the industry and the company, Fernandez (2007). According to 
Fernandez (2007), anyone working in Corporate Finance must understand the 
mechanisms involved in company evaluation, not only because of its importance for 
valuing M&A, but also because identifying the sources of creation and destruction of 
the company’s economic value is fundamental.  
2.2) Methods of evaluation  
There are various models for evaluating companies. Hence, the first step is precisely to 
select which method to use, based on each model’s diversity and complexity, and 




features implemented by each author. In this case, and in order to simplify this 
process, the perspective by Damadoran (2006), dividing assessment methods into four 
categories, will be considered: 
 Discounted Cash Flow Valuation; 
 Liquidation and Accounting valuation; 
 Relative Valuation; 
 Contingent Claim Valuation. 
The following table presents the models that can be used in each of the 
abovementioned methods, according to Damodaran (2006): 
Table 1 - Methods of evaluation 
Discounted Cash Flow (DCF) 
Liquidation and Accounting 
valuation Relative Valutation 
Contingent Claim 
Valuation 
Equity DCF Models:  - Book Value Multiples:  - Black Scholes 
 - Dividend Discount Model (DDM)  - Liquidation Value  -   - Binomial Value 
 - Free Cash Flow to Equity (FCFE)   - Fair Value Valuation  - PE   
Firm DCF Models    - PBV   
 - Free Cash Flow to Firm (FCFF)    - PS   
 - Economic Value added (EVA)       
Adjusted Present Value (APV)       
 
2.2.1 Discounted Cash Flow (DCF) 
In an evaluation using the discounted cash flow, the value of an asset is the present 
value of expected cash flows of the asset, discounted at a rate that reflects the risk of 
those cash flows. The use of DCF is also considered somehow an act of faith, as it 
assumes that each asset has an intrinsic value, and tries to estimate this value based 
on its characteristics, Damodaran (2006). 




The evaluation of discounted cash flows is based on future cash flows and discount 
rates. Given these data, this approach is easier to apply to assets (companies) whose 
cash flows are currently positive and can be estimated with sufficient reliability for 
future periods, where a proxy for the risk can be used to obtain discount rates. The 
closer one gets to this idealized scenario, the more difficult it is to assess the cash 
flows, Damodaran (2002). 
Although there are many DCFs, this study will focus on the most consensual and widely 
used methods for evaluating companies. 
As summarized in Table 1, this study will refer the following methods: 
 Equity Discounted Cash Flow Models; 
 Firm Discounted Cash Flow Models; 
 Adjusted Present Value. 
2.2.1.1 Equity Discounted Cash Flow Models 
The market value of a company’s equity is obtained by updating the equity’s cash flow 
to a return rate of the company's equity. When this value is added to the market value 
of the financial debt, it is possible to determine the total value of a company, 
Fernandez (2007). 
There are two models in this category: 
 Dividend Discounted Model (DDM); 
 Free Cash Flow to Equity (FCFE). 
 




 Dividend Discounted Model (DDM) 
 
The cash flow models based on discounted dividends are the oldest, but many analysts 
abandoned these methods, considering them too conservative. However, many of the 
discounted cash flow models are founded on dividends. According to this model, the 
value of an asset is represented by cash flows from dividends generated by the asset, 
discounted at the risk rate required by investors (K ), i.e., the equity return rate. The 
cash flows from dividends and the equity return rate are the two model indicators. To 
obtain the expected dividends it is necessary to consider certain assumptions on 
payout and dividend growth rates. The equity return rate can be calculated using the 
CAPM, through the Beta factor in arbitrage, and in multi-factor models, Damodaran 
(2006). This model has been studied for a long time, having been Williams (1938) the 
first author to identify the correlation between the share value and dividends. Durant 
(1957) created a variant for the DDM model, but Gordon (1962) was the one who 
popularized the model. In addition to the indicators of the initial model, this model 
also considers a growth rate constant, (g). The model has two important 
considerations for calculating growth rate:  
- Considering that the dividend growth rate is perpetual, it cannot exceed the income 
growth rate;  
- Second, it is considered that other performance measures may have a growth equal 






Fuller and Hsia (1984) created a new variant of the Gordon model, the H. Model. This 
model considers two stages of growth rate, a stable growth phase and variable growth 




phase, bypassing problems associated with abrupt changes in growth rate, when 
transitioning to the stable growth rate phase.  
P =
DPS 	 × (1 + g )
(r −	g )
+ 	
DPS × H × (g −	g )
(r −	g )  
 
The great advantage of this model is its ease of application and calculation. 
Nonetheless, it has some limitations, especially regarding the cash flow applied to 
shareholders, as it is normal for companies to retain incomes, withholding some of the 
capital available. Consequently, this will result in a higher FCFE than DDM, thus 
adulterating the model, Damodaran (2006). 
 Free Cash Flow to Equity (FCFE) 
The FCFE model follows much of the DDM model’s logic. It differs in the fact that, 
instead of cashing the actual dividends, it discounts the potential dividends. 
Damodaran (1994) defines the model as a way to capture the free cash flows after 
necessary reinvestment and payment of financial debt have been made. 
 




The use of this model is especially appropriate for shareholder restructuring, such as 
M&A, and for evaluating financial institutions, because in these situations it is 
necessary to jointly assess the operating and financial decisions, Goedhart (2005). This 
model was calculated and is available in the annex only for information purposes. 




2.2.1.2 Firm Discounted Cash Flow Models 
These models are an alternative to equity-based models. In this case, the company is 
evaluated as a whole, considering the total investment, i.e. equity and financial debt. 
The model is built based on an average capital ratio, combining the equity return rate 
with the foreign capital return rate. In these models, it is also important to consider 
that there are tax benefits due to the use of financial debt, Damodaran (2006). 
The most relevant models within this category are: 
 Free Cash Flow to Firm (FCFF); 
 Economic Value Added (EVA). 
 
 Free Cash Flow to Firm (FCFF) 
An assumption of the FCFF - as for the FCFE model - is the application of a continuous 
growth (g). Hence, the basis of the following year’s FCFF model is the average capital 
cost rate and the perpetual growth rate. 
Company	Value =
FCFF
WACC −	g  
Following the FCFE Model, the FCFF model shares the same conditions: 
 The growth rate cannot equal or exceed the economic growth; 
 The company's characteristics must be consistent with the assumptions of 
growth stability, namely, the reinvestment rate used to estimate the cash flows for the 
company must be consistent with the stability of the growth rate. 




These assumptions were analyzed by Miles and Ezzel in 1980, who concluded that it is 
possible to achieve a tax benefit with perpetual growth by upgrading these cash flows 
to the cost of equity rate, Damodaran (2006 ). 
FCFF = Operating	Cash	Flow− Expenses − Taxes − Change	in	NWC
− Changes	in	Investments 
 Weighted Average Cost of Capital (WACC) 
WACC is calculated by weighting the debt cost (Kd) and the equity cost (Ke) on the 
company's financial structure. This is the appropriate rate for situations in which we 
evaluate the company as a whole (debt and capital), considering the required equity 
return according to the proportion of capital invested by each party, Fernandez (2007). 
WACC = 	
E
E + D 	× K + 	
D
E + D 	× K 	×
(1− T) 
Hence, the variables Tax Rate, Equity and Financial Debt Capital are calculated directly, 
whereas for the calculating Ke and Kd rates it is necessary to rely on assumptions. This 
model was calculated and is available in the annex only for information purposes. 
 Equity Cost (Ke) 
Equity’s return rate is defined as the rate that investors require for their investment. In 
order to estimate this indicator, it is necessary to determine the expected return rate 
of the company's shares. As expected return rates are unobservable, we use prefixing 
models of risky assets that translate into expected return. 
The most common model used for calculating this rate is the Capital Asset Price Model 
- CAPM (Sharpe 1964). However, there are other models, such as the Arbitrage Price 




Model - APT (Ross 1976) and the three factors model, by Fama and French (2004). 
These designs differ mainly in the way they define risk. 
The CAPM defines the risk of an action as its sensitivity to the stock market, being the 
most common, Goedhart et al (2005a). 
E(R ) = 	R + 	β × 	E[R −	R ] 
 
 Risk Free Rate ( ) 
According to Damodaran in his article "Estimating Risk Free Rates", there are two 
essential requirements to define a risk-free rate: 
"There can be no risk default associated with its cash flows" and; 
"There can be no reinvestment risk." 
In order to consider that there is no risk, one cannot consider companies because they 
lack the ability to issue currency, unlike countries. Hence, the selection should be 
performed from countries at no risk of default, and there are no better candidates for 
this than countries with AAA rating. 
For this reason, and because we are considering companies located in Europe, the best 
basis for defining a risk-free interest rate is the German government bonds, since it is 
one of the few countries meeting the requirements for selecting a risk-free rate. 
 Beta ( ) 
The Beta coefficient is an indicator that measures the risk, having two key features for 
the calculation process: 
- First, the Betas measure the added risk in a diversified portfolio instead of total risk; 




- Second, the Betas measure the relative risk of an asset, standardized in value 1. 
Betas can be calculated based on the unlevered industry’s Beta, because the sector is 
exposed to similar operational risks. Thus, Beta can be calculated using the following 
formula, Damodaran (1999): 
β = 	 β 	[	1 + (1 − t)
D
E	] 
Another way to calculate Beta is through a linear regression between the asset returns 
and the index returns, using the following formula, Damodaran (1999): 
E[R ] = a + 	β + 	E[R ] 
 
 Market risk premium ( ) 
This indicator reflects the market risk and can be divided into three classifications, 
Damodaran (2012): 
 Award Required - Extra value demanded by investors in order to invest in risky 
assets; 
 Award History - Difference between the average returns of the market 
portfolio and the risk-free interest rate; 
 Implicit Award – Future estimation based on market rates or asset prices 
traded today. 
 
According to ERSE (2014), the risk award for investors to invest in risk assets in 
Portugal is 6.25 %. 





 Cost of Debt ( ) 
Debt cost is the rate that financial lenders require to invest capital. The best way to 
estimate this value is to consider the yield to maturity of a long-term obligation 
that is sold in the secondary market. 
Another way to estimate debt cost to companies that do not issue bonds is using 
the default spread, plus the interest rate without risk, Damodaran (2002). 
 Economic Value Added (EVA) 
According to Ferreira (2002), EVA is " ... a concept perfectly articulated with the new 
financial theory, where the value of a company is equal to the sum of updated cash 
flows for shareholders and creditors... '. This is an indicator that arose from minor 
changes to a previous one, named "Residual Income". 
This concept exists since 1777, although it has evolved over the years with several 
names, having first been named "Residual Income" in 1965 by Anthony and Solomons. 
In 1995 it was named "Economic Profit" by Copeland and Murri, and finally in 1990 the 
company Stern & Co. assigns its current designation, "Economic Value Added". This 
indicator arose from the need to create value for shareholders, being Rappaport, with 
his article Harvard Business Performance (1981) and book Greating Shareholder Value 
- The New Standard for Business Performance (1986), one of the main drivers of this 
movement. This ended up resurrecting this metric, as mentioned Neves (2011) 
"...having finally left the academic books and passed to the business practice.". 
EVA is a more effective form of performance evaluation, as it considers all the financial 
investment in the company: by the capital holder, by financial creditors, and 




considering the interest rates required by each party. Finally, these interest rates are 
applied to the operational income created during the reviewed period, thus obtaining 
the net value created for shareholders. 
For Martin and Petty (2000), their definition of EVA is no more than a new metric 
improved by economic profits. 
EVA = NOPAT − WACC	 × CI 
 
2.2.1.3 Adjusted Present Value Model (APV) 
The APV model separates the effect of the financial debt from the value of the assets 
associated with the business. This model starts with the evaluation of the unlevered 
company. Afterwards, the effect of the debt and the resulting tax benefits associated 
with this debt are added. The first attempt to isolate the tax benefits of debt was from 
Modigliani (1963), using the cost rate debt as refresh rate of a perpetuity. The current 
form of the APV model was presented by Myers (1974) as the relationship between 
investment and financing decisions, Damodaran (2006). 
In this model the evaluation is done in three steps, beginning with estimating the value 
of the company without debt, then considering the updated value of the debt tax 
benefits, and finally assessing the probability of default and its respective cost through 
the effect of contracted debt, Damodaran (2006). 
 First Step: 
	 	 	 =




 Second Step: 




	 	 	 = 	




 Third Step: 
 
	 	 [ ] = ( 	 	 ) × ( 	 	 	 ) 
 
The advantage of this model relies on its ability to separate the debt effect on its 
several components, allowing the analyst to use different refresh rates for each 
component. The major drawback of this model involves the difficulty in estimating the 
probability of default and cost, Damodaran (2002). 
3) Luz Saúde, S.A. 
3.1) Company and business presentation  
After being aquired by Fidelidade - mostly (80%) controled by the Chinese company 
Fosun -, Espírito Santo Saúde became Luz Saúde, S.A.. This open society saw its capital 
be almost entirely acquired (96.067%) on 17 October 2014, with a price per share of € 
5.01, representing a total investment of 478 million euros. By the end of the fiscal 
period of 2014, Luz Saúde was held by Fidelidade on 98,2%. 
Luz Saúde Group is one of the largest players in the private health sector, a market 
dominated by four entities: Mello Group, Luz Saúde Lusíadas and Trofa Saúde, 
representing 83% of the market, Luz Saúde appears in second place with about 25% 
market share, behind the Mello Group, holding a position of approximately 40% in the 
market. 




The story of this successful group began in 2000, with the acquisition of a majority 
stake in the capital of CLIR, owner of Aveiro Private Hospital and the Arrabida Hospital. 
It has since undergone various processes of M&A, and construction involving private 
Hospitals, clinics and even senior residences. 
The group currently owns 8 private hospitals, 7 ambulatory clinics, 1 private hospital in 
a PPP regime, and 2 local senior homes. 
The Lusíadas Saúde Group, formerly known as Private Hospitals of Portugal, SA, was 
acquired on March 1, 2013 by the Brazilian Amil Group for ca. 85.6 million euros. The 
group was renamed to Lusíadas Saúde immediately following the acquisition.  
This is one of the largest players in the private health market, including the third 
largest brand, behind Mello and Espirito Santo Saúde Group, with a share market of 
approximately 23%. 
The Lusíadas Group began operating in March 1998, still under the Private Hospitals of 
Portugal designation, managing the Hospital Privado dos Clérigos, immediately 
launching the construction of Boavista Private Hospital. 
Today it is one of the most important brands within the private health sector, owning 4 
Private Hospitals, 4 Clinics and 1 Private Hospital under PPP regime, employing 4000 
professionals. 
The Mello Saúde Group was the first entity to work in the health sector in Portugal. It 
started its activity in 1945, with the inauguration of the Hospital CUF Infante Santo. 
Nowadays, it is the largest business group in the health area in Portugal, with ca. 40% 




of the market share and, because it is not quoted on the stock market, it continues to 
be a closed group without dispersed capital. 
It currently comprises 6 private hospitals, 5 private clinics, 1 institute, 2 hospitals under 
PPP regime, and a insurance and work health organization, with a staff of about 7000 
employees. 
3.2) Operational Performance  
Luz Saúde has shown some variation in terms of performance indicators over the last 
five years, similarly to competing companies. However, the results have always been 
positive with the exception of the year 2012, when the net result dropped to negative 
levels, inverting the position of the previous years. 
Table 2 - Data from last 5 Years 
2014 2013 2012 2011 2010 
Sales 
       
399.315.006   
       
371.051.493   
       
338.962.694   
       
272.552.505   
       
248.837.899   
Δ 7,62% 9,47% 24,37% 9,53% 16,07% 
EBITDA 57.729.415 58.471.458 38.788.905 47.427.273 39.896.886 
Δ -1,27% 50,74% -18,21% 18,87% 24,52% 
EBT 23.016.987 20.518.580 -2.021.512 9.085.052 2.780.823 
Δ 12,18% 1115,01% -122,25% 226,70% -177,65% 
Net Profit 18.099.909 14.051.602 -2.033.019 4.779.655 1.429.337 
Δ 28,81% 791,17% -142,53% 234,40% -142,53% 
 
 Sales  
Through a detailed analysis of Luz Saúde business’s volume, it is possible to see a 
continuous growth over the reviewed period, reaching its highest relative growth 
compared to the previous period in 2012, with a value of 24.3%. Furthermore, it 




should be noted that the turnover growth between 2010 and 2014 was approximately 
60%. This growth reflects the overall improvement of the activity either in outpatient 
or inpatient. 
 EBITDA 
As in turnover, the operating cash flows trend has been positive and increasing over 
the period, excluding the year 2012 when, despite the increase in turnover, EBITDA 
suffered a break cost, associated with the inauguration of Hospital Beatriz Ângelo. In 
the year 2014 there was also a slight fall of 1.27% in operating profitability. 
Furthermore, between 2010 and 2014, the EBITDA growth was approximately 44%. 
 Operational information 
In operational terms, analyzing the data presented in Table 4, we see that there 
were positive developments in every area of intervention during the period under 
review; the number of visits increased by 59%, the number of emergency room 
visits increased 103%, the number of surgeries and deliveries increased by 68%, 
and the number of employees grew by 59%. Although there is no data regarding 
number of imaging exams and number of beds in 2010 and 2011, growth between 
2012 and 2014 was 28% and 4%, respectively.  
Tabla 3 - Operational Data 
2014 2013 2012 2011 2010 
Number of Medical 
Appointments 
          
1.617.000   
          
1.517.000   
          
1.323.000   
          
1.131.000   
          
1.016.000   
Number of emergency calls 
             
540.000    
             
486.000    
             
413.000    
             
281.000    
             
266.000    
Number of surgeries and 
births 
               
56.900    
               
49.400    
               
45.700    
               
37.600    
               
33.900    
Number of exams of 
Imagiology 
             
979.000    
             
878.000    
             
765.000     N/D   N/D  
Number of beds 
          
1.179.000   
          
1.179.000   
          
1.131.000    N/D   N/D  
Number of employees                                                                                 




9.200    9.000    8.400    6.300    5.800    
 
 Structural Information 
Investment in Capex has fluctuated over the reported period, in which 2010, 2012 and 
2014 were the periods with higher investment, following hospital facility improvement 
undertaken during those years. 
The Working Capital Fund has shown great volatility in 2010, 2012 and 2013 with 
negative results, meaning that the permanent capital is not covering long-term needs, 
and needs to finance fixed assets with short-term liabilities. In 2011 and 2014 this 
indicator was more balanced, ending the permanent capital to fund short-term 
operations. These oscillations are largely due to changes in long-term financial debt 
and equity oscillation. 
The net debt has been reduced over that period, a decrease of 42% between 2010 and 
2014 with no effect on cash and equivalents. 
Another indicator that has improved over the reporting period is the financial net debt 
due to the EBITDA. In 2010 the company needed 7 years of operational activity to 
settle all financial debt, and in 2014 it would only take three years to settle the 
financial debt capital, a time reduction of 60%. 
Tabla 4 - Structural Data 
2014 2013 2012 2011 2010 
CAPEX 
        
28.300.000    
        
12.500.000    
        
27.117.325    
          
6.819.642    
        
24.425.517    
Working Capital 
          
8.508.915    
-       
31.495.327    
-       
52.173.747    
        
83.768.122    
-       
33.323.546    
NET DEBT 
       
171.975.872   
       
171.104.746   
       
204.295.296   
       
271.987.270   
       
297.038.364    
NET 
DEBT/EBITDA 
                       
3    
                       
3    
                       
5    
                       
6    
                       
7    





3.3) Market Performance, Stakeholders structure 
Luz Saúde, S.A. has been publicly listed on Euronext Lisbon since February 12, 2014, 
incorporating the general index of the country, PSI - GENERAL. 
Analyzing plot 1, we can identify major fluctuations, reaching its maximum on 10 
October 2014 with a value of € 4.98 per share. On the other hand, the minimum value 
was reached on 10 December 2014, with a value of 3.11€ per share. It was in this 
period - between October and December - that we saw increased volatility in share 
price. We can define two limits between which the share price was kept during 2014, 
positively never exceeding 5.00€ and a negative value of 3.00€. Despite the oscillations 
detected between February 12, 2014 and December 31, 2015, the overall share price 
increased during that period. 
When comparing the share to the index, we find that the first performed better than 
the second, as the index devalued in the reference period, losing more than 700 
points. 




Plot 3 - Price PSI GERAL vs LUZ SAÚDE 
 
Regarding daily variations, when we compare the index to the share alone, we note 
that the share has a higher daily volatility, with much pronounced fluctuations than 
those recorded for the index. The peak volatility for Luz Saúde, S.A. was registered, as 
abovementioned, between October and December 2014, while the index has 
remained relatively stable. 
Plot 4 - Fluctuation PSI Geral vs Luz Saúde, S.A. 
 
Through a public offer of aquisition, Fidelidade - Companhia de Seguros S.A. 
acquired 96.067% of the capital of Luz Saúde, at a price of 5.01€ per share, thus 





















Luz Saúde PSI Geral




Companhia de Seguros S.A. held 98.23% of the company’s equity capital, 
representative of 93,851,156 shares of a total of 95,542,254. 
4) National Economic Perspective and the Sector 
After a time of great uncertainty and difficulties, during which several consecutive 
negative growth rates were recorded for the Portuguese economy, economic growth 
resumed in 2014. This year registered an increase of GDP of 0.9%, marking the 
emergence of a new cycle, based on estimates from the Bank of Portugal, with 
expected economic growths of 1.7% in 2015, 1.9% in 2016 and 2% in 2017. 
With sustained growth in private consumption accompanied by an increase in 
disposable income, and an acceleration of gross fixed capital mainly in the business 
sector, it is expected that domestic demand presents a short-term moderate growth. A 
gradual and moderate unemployment reduction in coming years is also expected, as a 
result of good prospects for the national economy. 
Finally, a stabilization of the consumer’s price harmonization index in annual terms is 
projected for 2015, with an increase of 1% in 2016 and 2017, according to the 
moderate growth of the Portuguese economy. 
The Private Health market is expected to increase along with the estimates for the 
Portuguese economy, and in line with the growth recorded in this market in recent 
years. 
Portugal has the world’s second lowest fertility rate and a representative elderly 
population, corresponding to ca. 10% of the total population. Hence, a pronounced 
growth of senior health offer is expected, especially in health insurance, health plans 




and senior residences. The market for health insurance, very influent in the private 
health care market, has recently registered an increase of 3%, indicating that this 
growth will persist in the short term. 
Another important factor in private healthcare is the State’s need to reduce public 
debt, which will cause an investment reduction in the health sector and, consequently, 
the regression of the services offered. This is one of the main aspects in which private 
healthcare has found a niche, presenting considerable interest in improving and 
diversifying their services and equipment in order to attract clients from the public 
sector. 
Hence, it is expected that the private healthcare sector keeps growing during the next 
years - as occurred during the crisis -, especially due to the growth in insurance and 
health plans, and to the increased service offer and equipment quality. 
4.1) Sector Analisys 
 
 ROI 
The rentability of invested capital, as stated above, is reflected in the operating return 
rate of equity and financial debt capital’s sum. Analyzing the ROI chart (appendix), we 
can conclude that the market trend is growth, mainly due to the increase in EBIT, since 
capital growth has canceled the reduction of financial debt. Luz Saúde’s behavior has 
been steady over the reviewed period, with a positive slope.  
 ROE 
Although the ROE plot does not allow us to identify volatility, the truth is that the 
entire market has seen a lot of instability in this indicator. Regarding Luz Saúde, this 
instability is due to the net profit variation associated with some changes in equity. As 
in the previous indicator, the growth trend is common throughout the sector. 





For Luz Saúde, this metric has been unstable, varying according to the evolution of the 
operating results. Regarding the sector, the presented behavior is very similar to the 
one presented by the companies mentioned, ultimately following the same path in 
general terms. 
 Leverage 
Liability has been a major concern for companies in the health sector. Analyzing the 
leverage of the chart, we see that every company in the sector has high liability values. 
However, Luz Saúde is in a more convenient level than the others. It is the intention of 
the analyzed companies to reduce their liability by reducing financial debt, either by 
increasing the equity and reducing financial debt. 
 Leverage Structure 
The weight of current liabilities’ in total liabilities is pivotal for identifying the 
percentage of commitments that exist in short term, considering all obligations. Luz 
Saúde presents many variations due to changes in short-term financial debt. In 
general, the market has revealed some variations, registering a general trend towards 
reduction of short-term debt. Luz Saúde is in a better position than its competitors. 
 Debt Payment 
In terms of estimating the time required for settling the debt, we can see a very 
positive evolution, both in Luz Saúde and throughout the sector. This is essentially due 
to the objective of reducing financial debt in the market. 




5) Strategic analysis 
5.1) SWOT Analysis 













Internal focus of business expansion
Client satisfaction
Financial robustness of the structure
Presence in masses locations 
Strong sence of social responsability
Search for inovation
Ambitious and productive investments 




Long average time for receiving payments 
Operational volatility 
Structure relying in costs
Financial debt concerntrated in comercial 
paper
Market in constant growth
Internationalization
Developing strategic partnerships
Expansion in the internal market
Investment in new Technologies
Investing in alternative medicines





Brand affected by the BES effect
Market stagnation








Possibility of entering 
competitors 
Rivalry among 
companies within the 
sector














Luz Saúde will be evaluated according to the Absolute Value method, determining the 
company's value as a whole in absolute terms. 
The absolute value will be determined by the FCFF method. Despite all the methods 
presented in this study, FCFF remains the most commonly used by investors and 
managers in business valuation. It is also the best method to apply in this case since 
the financial framework has an important weight in the economic structure of the 
company. We will calculate the three most relevant models of FCFF method: FTE 
model, APV and WACC. The FCFF will be designed for a time frame of three years- 
named explicit period- and a final period, considered perpetual. Afterwards, the 
adjusted FCFF will be discounted to the corresponding rates, taking into account each 
of the models in both the explicit period and perpetuity. 





INTENSITY OF INDUSTRY COMPETITIVENESS





To calculate the company's value in absolute terms, a set of assumptions were defined, 
such as the projection of FCFF and the refresh rate that will be presented immediately. 
6.2.1) Turnover 
The turnover was estimated and calculated for the next 3 years of explicit period and 
for the perpetual period, with a standard growth rate of 0.5% of the turnover for the 
previous period. 
The Bank of Portugal estimates a GDP growth for 2015, 2016 and 2017 of 1.7%, 1.9% 
and 2% respectively. However, the political instability that currently exists in Portugal, 
and the fact that there appears to be a tendency for turnover stabilization based on 
the historical period 2010-2014, must be acknowledged. 
6.2.2) EBITDA 
EBITDA was calculated taking into account the historical evolution and the turnover. 
First, the EBITDA margin for each historical period from 2010 to 2014 was determined. 
Afterwards, the average indicator was calculated and applied to the turnover for the 
explicit and perpetual period. 
6.2.3) Investment in non current assets and depreciations 
Luz Saúde does not have a defined investment policy, but based on the historical 
period, we can see that there is a general pattern. Historically, Luz Saúde has a two 
investment cycle in two years, i.e. investment happens at t, and again only at t + 2. 
To calculate the explicit and perpetual period we considered the average CAPEX of the 
historical period, and applied it to the turnover of each year. 
CAPEX calculation is performed according to the following formula: 




= 	 	 −	 	 	 + 	
+ 	  
The process of estimating depreciation and amortization was performed the same way 
used for investment, the average depreciation and amortization was calculated on the 
historical period, and applied to turnover in each of the explicit and perpetual periods. 
6.2.4) Investment in working capital 
To estimate the investment in working capital - an indicator that compiles various 
items of assets and short-term liabilities (inventories, accounts receivable, EOEP, other 
current assets, suppliers, bills to pay, other current liabilities) - we calculated the 
average of each rubrics for the explicit period, and later applied it to turnover in each 
of the estimated periods. 
6.2.5) Risk-free Assets 
The risk-free rate used for the assessment corresponds to the German treasury rate, 
thus fulfilling the no risk interest rate parameters mentioned in the literature review. 
According to Bloomberg, the risk-free interest rate with a maturity of 10 years, was 
rated 0.13% on 15 April, 2016. 
6.2.6) Cost of Debt 
To determine debt cost, three values are presented, corresponding to three forms of 
calculation: 
 Risk Model and Company Failure - 7.63%;  
 Risk Model and Country Failure - 3.38%;  
 Rate in the report and accounts - 3.12%. 
Since Luz Saúde is not rated, the first formula, which considers the risk model and 
company default, is immediately excluded. 




The second formula, taking into account the country risk would be the most 
appropriate if there were no information on the cost of debt capital. However, with 
the information provided in the report and the company's accounts, it was possible to 
obtain the rate demanded by creditors - which is the most accurate - and apply it 
during the study. Hence, the cost rate of debt capital used in the study was 3.12%. We 
can also conclude that Luz Saúde is doing a good job in terms of financial costs, since 
the profitability provided to creditors is inferior to every estimate obtained. 
6.2.7) Beta 
The beta used in this study was extracted from the Damodaran website, with the value 
of 0.95. Due the small number of observations in the stockmarket, we were unable to 
obtain a reliable Beta, which lead us to eventually choose the Damodaran site. 
6.2.8) Market Risk Premium 
According to a study by ERSE, the risk prize of the Portuguese market will be 6.25% 
between 2015 and 2017, which is the rate applied during the study. 
 
6.2.9) Tax Rate 
The tax rate used was the corporate tax rate used in 2015 (21%), corresponding to the 
nominal rate on taxable income in the 2014 period. 
6.2.10) Equity weight and Financial Debt 
The economic structure of Luz Saúde has been subjected to fluctuations over the 
analyzed period. We can see that there is a steady increase in equity, developed 




between 2013 and 2014. Regarding financial debt, the company’s policy has been to 
reduce external dependence, which culminated in a 33% reduction from 2010 to 2014. 
This position reflects the company's interest in reducing the D/E ratio. 
6.2.11) APV (Adjusted Present Value) 
The APV model was used in this evaluation, in addition to the WACC and FTE models. 
However, taking into account the level of financial debt and its weight in Luz Saúde’s 
structure, it is important to assess the tax shield arisen from using this debt. For this 
reason, the APV model was considered the best model to evaluate Luz Saúde using the 
R rate, 5,13%. 
6.2.1) Long-Term Growth Rate 
The growth rate used in perpetuity was 0.5 %, considering this an acceptable value 
contrasting with the historic information of the Portuguese economy. 
6.3) FCFF of Company 
After applying all criteria mentioned in the preceding paragraphs and in the literature 
review, we obtained the following FCFF: 
  
Explicit Period Perpetuity 
  2014 2015 2016 2017 2018 
EBIT*(1-t) 24.145.216,46 19.608.574,98 19.706.617,85 19.805.150,94 19.904.176,70 
Depreciation 27.529.869,45 36.317.950,84 36.499.540,59 36.682.038,30 0,00 
Change Working Capital 28.602.009,58 2.900.666,92 5.316.838,58 5.318.422,77 5.320.014,88 
Capex 28.300.000,00 27.179.582,65 27.315.480,56 27.452.057,96 0,00 
FCFF -5.226.923,67 25.846.276,25 23.573.839,31 23.716.708,50 14.584.161,81 
 
We estimated a value of 66.33 million for the explicit period, and 271.25 million for 
perpetuity. 




7) Evaluation Results 
The evaluation of Luz Saúde was performed in absolute terms, taking into account the 
historical period 2010-2014, as well as other assumptions in terms of growth rates, 
yields and other market indicators. With all these indicators, it was possible to 
estimate the explicit period of three years and a perpetual period, which were used for 
the calculation of FCFF, being later discounted, thus obtaining its valorization. Because 
the company has a considerable financial debt, it was also important to calculate the 
effect of the Tax Shield and value this indicator. The Firm Value was calculated from 
the sum of the discounted FCFF, plus the tax effect, other current and non-current 
assets, deducting other current and non-current liabilities. Based on Firm Value, the 
company's equity was calculated, adding the value of financial debt existing in the 
2014 period. 
 
Value of Operations Explicit 
 
         66.328.633,04 €  
Value of Operations Perpetuity 
 
       271.244.949,25 €  
Tax Savings 
 
       123.865.247,81 €  
Other Assets 
 
       352.984.837,78 €  
Other Liabilities          178.282.178,94 €  
Firm Value 2014          636.141.488,95 €  
   Debt 2014 
 
       192.656.555,98 €  
Minority 2014                                    -   €  
Equity Value 2014          443.484.932,97 €  
Shares            95.542.254,00 €  
   Price Target                               4,64 €  
 
The intrinsic value of each of Luz Saúde’s share obtained in the evaluation was 4.64€. 
This represents a potential appreciation of 22% on the share price on 31/12/2014, and 
an increase of 56% over the most recent share price (03/24/2016). It is important to 
mention that the obtained value is not accurate because the assessment was based on 




certain economic and sectorial assumptions that in the future may not be realized. 
Hence, a sensitivity analysis will estimate with a greater degree the range of values 
that this price may assume. 
8) Sensitivity analysis 
The variables that are most relevant to analyze its impact on Luz Saúde are the 
perpetual growth rate and the risk-free interest rate. 
g 4,64 Δ 
0,20% 4,49 -3,28% 
0,40% 4,59 -1,14% 
0,60% 4,70 1,19% 
0,80% 4,81 3,72% 
1% 4,94 7% 
1,20% 5,09 9,55% 
1,40% 5,24 12,93% 
1,60% 5,42 16,68% 
1,80% 5,61 20,88% 
 
In a ceteris paribus scenario, the g variable undergoes changes, strongly affecting the 
share value. For example, a simple change of 1% has an impact of 7% in share value. 
  4,64 Δ 
2,60% 5,06 9,01% 
2,80% 4,87 4,91% 
3,00% 4,72 1,62% 
3,20% 4,59 -1,06% 
3,40% 4,49 -3,30% 
3,60% 4,40 -5,19% 
3,80% 4,33 -6,82% 
4,00% 4,26 -8,22% 
4,20% 4,20 -9,45% 
 
Performing another ceteris paribus scenario, it appears that variations in the variable 
R  will - as observed with the variable g - strongly affect share value, e.g., for a 
variation superior to 1%, the share value will vary over 9%. 









4,64 0,20% 0,40% 0,60% 0,80% 1,00% 1,20% 1,40% 1,60% 1,80% 
2,6% 4,91 5,01 5,12 5,23 5,36 5,51 5,66 5,84 6,03 
2,8% 4,72 4,82 4,92 5,04 5,17 5,31 5,47 5,65 5,84 
3,0% 4,56 4,66 4,77 4,89 5,02 5,16 5,32 5,49 5,69 
3,2% 4,44 4,54 4,65 4,77 4,89 5,04 5,19 5,37 5,56 
3,4% 4,34 4,44 4,54 4,66 4,79 4,93 5,09 5,26 5,46 
3,6% 4,25 4,35 4,46 4,57 4,70 4,84 5,00 5,17 5,37 
3,8% 4,17 4,27 4,38 4,50 4,63 4,77 4,92 5,10 5,29 
4,0% 4,11 4,21 4,31 4,43 4,56 4,70 4,86 5,03 5,22 
4,2% 4,05 4,15 4,26 4,37 4,50 4,64 4,80 4,97 5,17 
 
Compiling the two previous assumptions, the growth rate (g) and the risk-free rate R , 
ceteris paribus, it is possible to see that the most positive oscillation within the 
presented scenarios will value the share price to 6.03€, while in worse scenarios the 
share price would lose value to 4.05€. 
This analysis ends up giving more confidence to the presented values, and it is possible 
to see that the value of the share is undervalued. 
9) Conclusions 
Luz Saúde has great potential for future growth. Over the past five years this company 
demonstrated resilience to the global financial crisis, and its adversity, managing to 
continually fulfill their objectives. Its operating performance is mainly explained by a 
turnover increase, a direct consequence of increasing the number of health facilities 
and investment in service quality. Continuing to follow this expansion and 
diversification strategy, and presenting a differentiated service/product that offers a 
good quality/price ratio to the customer, it is expected that this company will continue 
to grow. Destinations for international expansion are still unexplored, which might be 
part of the short term strategy, specifically for emerging markets and PALOPs, resulting 
in an opportunity to take into consideration. 




Despite having numerous opportunities for growth, the group also has important 
challenges ahead. One is related to its EBITDA margin; the group must be able to 
regain their margins to the values presented in beginning of the financial crisis (16%), a 
task that will be challenging for two reasons: (i) health services have high operating 
costs because of the need for highly qualified human resources, implying larger 
salaries, and (ii) providing a differentiated service requires a higher demand and 
quality level. Another challenge for Luz Saúde is to reduce the weight of its debt, due 
to the company’s weight of high Net Debt. It is also important to note the average time 
of customer receivables and consequently the reduced liquidity that arises in order to 
avoid cash flow problems. Finally, the company’s last challenge will be to maintain the 
level of excellence in services within their institutions, and maintain sustainable 
growth. 
From the results obtained in the company’s evaluation and in the sensitivity analysis, 
one can conclude that the price of Luz Saúde’s shares on 31/12/2014 is undervalued; 
even considering the worst case scenario, the share price is still lower than its real 
value. The results of the sensitivity analysis also allows us to state with a higher degree 
of certainty that the intrinsic value of the company's shares on 31/12/2014 would be 
between 4.05€ and 6.03€. So, buying recommendation of Luz Saúde’s shares would be 
given to future investors on that date, because the market would eventually recognize 
their true value, and consequently, the rise of share price would provide investors 
returns higher than 7%, within a time period of 12 months.  
We also performed the FCFE and WACC models, retrieving values of 4.70€ and 3.83€ 
respectively. The FCFE model was not considered for the evaluation due to its implicit 




valuation of the company from the viewpoint of equity investor, excluding the 
investor's debt capital. The WACC model would be one of the models to consider 
because, as the APV model, it considers the evaluation of the company from the equity 
and debt capital perspective. However, one cannot assess the benefits of financial debt 
separately. This model retrieved a value closer to the market value, at the time of 
evaluation.  
Regarding future research, it would be interesting to evaluate the impact of the 
construction of Hospital Beatriz Ângelo on Luz Saúde’s accounts, as well as the effect 
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Annex 1 – Alternative evaluation methods 
 Liquidation and Accounting Valuation 
The Liquidation and Accounting Valuation method is based on the evaluation of assets 
existing in the company using value or book value accounting estimates as a starting 
point, Damodaran (2006). 
This evaluation method is based on three models: Book Value, Fair Value and 
Liquidation Valuation. 
The book value consists in the evaluation of assets based on their book value. Daniels 
(1934) states that usually the financial statements represent the actual value of the 
company, serving as meeting point between the buyer and the seller. The evaluation 
based on this model has to follow certain rules: (i) for a fixed asset value one should 
consider the acquisition value with subsequent depreciation; (ii) in the case of a 
current active, the value is based on market value. Finally, there are other assets that 
can not be measured so easily. In conclusion, for companies with more weight in fixed 
assets and with few opportunities for growth, this evaluation model may be useful; for 
other types of companies this will not be the best model, Damodaran (2006). 
The fair value has been a hotly debated topic in recent years by accounting and 
regulators. Some believe it may bring useful information to the market, while others 
believe it can lead to manipulation of financial statements. This is not a very 
appreciated model in the finance world, as it is believed that only can provide a delay 
in market effect, Damoran (2006). 
The Liquidation Valuation presupposes the fact that the assets have to be sold 
immediately, the value obtained can be calculated in the same way that evaluations 
based on discounted cash flows, but with the liquidation effect which can download 
price of the asset. This is a method that can be used in economic difficulty with 
companies but in healthy companies would not be possible to translate their true 
market value, Damodaran (2006). 




In recent years, the fair value has been an intensely debated topic among accounting 
and regulators. Some believe it may bring useful information to the market, while 
others believe it can lead to manipulation of financial statements. This is a model that 
is not much appreciated in the world of finance it is believed that only can provide a 
delay in market effect, Damoran (2006). 
The Liquidation Valuation presupposes the fact that assets have to be sold 
immediately. The value obtained can be calculated in the same way that evaluations 
based on discounted cash flows, but considering the liquidation effect - which can 
download price of the asset. This method may be used in companies enduring financial 
difficulties, but for healthy companies it would not be able to describe their true 
market value, Damodaran (2006). 
 
 Relative Valuation 
This model is based on the demand of the market value of other comparable 
companies within the sector, following three essential steps:  
 Find comparable assets based on market values;  
 Scale market values to a common variable;  
 Adjust differences over assets.  
The Relative Valuation can converge to the same value of the discounted cash flows, 
but in order for that to happen, the market value of the assets must be correct. It is 
important to note that many equity researchers in M&A combine the method of 
discounted cash flows with the relative valuation method, Damodaran (2002 and 
2006). There is a wide variety of multiples for assets evaluation, which can 
differentiate into three types: (i) multiple based on market capitalization that are 




based on the price; (ii) multiple based on the company's value based on the company's 
value and (iii) multiple related growth, Fernandez (2002). 
 
 Contingent Claim Valuation 
The Contingent Claim Valuation model uses option price calculation models to 
evaluate assets: the binomial model and Black Scholes, Damodaran (2006). This model 
evaluates not only the company itself, but also the opportunities that may arise during 
the operation, variations that can happen, but that in a DCF model are not easily 
valued. It is considered a more complete model than DCF because contemplates 
exogenous variables such as asset price changes, expansions and technological 
developments, among others, Damodaran (2002) and Copeland and Keenan (1998). 
However due to the multitude of variables that this model needs, it becomes very 
difficult to use and apply practically Luehrman (1997). 
  




Annex 2 – Sector Ratios 
Plot 5 - ROI 
 
Plot 6 - ROE 
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Plot 8 - Leverage 
 
Plot 9 - Leverage Struture 
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Annex 3 – Five Forces of Porter 





1 – totally disagree
2 – disagree 
3 – statement is partly false and partly true
4 – agree
5 – agree completely 
Leave in blank if you don't know, or ir it is not applicable.
RATE
A. One can be small and enter the  business. 1
B. Competitor companies have unknown brands or clients are not faithful. 1
C. Low investment in infra-structures, credit to clients and products. 1
D. Clients will have low costs to change current suppliers. 3
E. Competitor technology is  not patented. Investing in research is not necessary. 1
F. The location, compatible with the competitors, w ill involve  low investment. 1
G. There are no demands from government benefiting existing companies ou limiting the entrance of new companies. 3
H. Established companies have little  experience in the business or high costs. 1
I A war between the new competitors is unlikely. 2
J The market is not saturated. o 4
TOTAL 18
Force 1 average = 1,80
10
RATE
A. There is a large number of competitors, with relative  balance regarding size and resources. 5
B. The business 's  sector shows s low grow th. Some prosper while others perish. 1
C. High fixed costs and pressurefor selling the  maximum possible to cover those costs. 3
D. Fierce price dispute among competitors. 3
E. There is not difference bewteen products/services comercialized by the  competitors. 3
F. It is vert expensive for established companies  to abandon the  business. 5
TOTAL 20
Force 2 average = 3,33
9
RATE
A. There is a large quantity of substitute  products/services. 5
B. Substitute products/services have lower costs than those from the existing companies. 3
C. Existing companies  usually do not use publicity to promote the ir  image and products /services. 3
D Product/service acting sectors are expanding, increasing the competitivity. 4
TOTAL 15
Force 3 average = 3,75
4
RATE
A. Clients buy in large quantities e  always press to get lower pr ices. 1
B. Product/service sold by the company represents a large part of the client's  costs and purchases. 3
C. Products /services  bought by clients  are Produtos/serviços que os clientes compram são standardized. 3
D. There are no s ignificant aditional costs to clients who change suppliers. 5
E. There is always the threat of clients be ing eventually able to produce the products /services aquired within the sector. 1
F. Product/Service sold is not essential for improving the buyer 's  products. 1
G. Clients are very well informed about prices and costs within the  sector. 3
H. Clients work  w ith flat profit margins. 1
TOTAL 18
Force 4 average = 2,25
RATE
A. Necessary product and servicesupply is concentrated in a few supplying companies. 4
B. Product/services aquired by existing companies  are  not easily replaced by others. 4
C. Existing companies  are not important clients  for suppliers.Empresas existentes no negócio não são clientes importantes  para os fornecedores. 2
D. Materials/services acquiredfrom suppliers are important for business success. 5
E. Products  bought from suppliers are differentiated. 3
F. Changing supplier involves  significative costs .Existem custos s ignificativos para se mudar de fornecedor. 3
G. Permanent threat of suppliers entering the  business sector 1
TOTAL 22
7  Force 5 average = 3,14
FORCES AVERAGE
Possibility of entering competitors 1,80
Rivalry among companies within the sector 3,33
Threat from substitute products 3,75
Buyers' negotiation power 2,25
Supplier's negotiation power 3,14
FORCE 3 - THREAT FROM SUBSTITUTE PRODUCTS 
FACTORS THAT DETERMINE THE INTENSITY OF THE SECTOR FORCES
FORCE 1- Possibility of entrance of new competitors
FACTORS
FORCE 2 - RIVALRY BETWEEN COMPANIES WITH THE SECTOR 
FACTORS
FATORES
FORCE 4 - BUYERS' POWER OR NEGOCIATION
FACTORS
FORCE 5 - SUPPLIERS' POWER OF NEGOTIATION
FACTORS




Annex 4 - Financial indicators 
Table 6 - Financial indicators 
  2010 2011 2012 2013 2014 
Equity 126.466.932,99 € 132.046.588,38 € 128.941.069,60 € 143.212.006,03€ 183.211.573,51 € 
Debt 308.007.941,77 € 305.317.675,32 € 228.556.259,84 € 205.923.306,56€ 192.656.555,98 € 
Working Capital 35.997.403,29 € 75.825.409,53 € 18.687.274,98 € 10.831.791,39 € 39.616.096,43 € 
Fixed Assets 292.098.216,61 € 272.538.216,73 € 271.194.631,23 € 253.873.748,34€ 256.009.328,45 € 
Cash Components 58.350.081,59 € 34.197.321,69 € 26.095.814,22 € 36.364.121,97 € 22.153.863,53 € 
Non-Operati. Assets 0,00 € 0,00 € 0,00 € 0,00 € 0,00 € 
Non-Operati. Liabilities 35.215.941,28 € 29.831.175,49 € 41.777.554,27 € 36.590.912,85 € 28.861.437,82 € 
 
Annex 5 – Financial Ratios 
Table 7 - Financial Ratios 
 
 
2010 2011 2012 2013 2014 Média
23,10% 24,42% 26,17% 29,98% 36,34% 28,00%
50,10% 59,13% 37,84% 36,94% 35,36% 43,87%
30,04% 32,32% 35,44% 42,81% 57,09% 39,54%
216,85% 242,10% 144,62% 123,22% 97,31% 164,82%
-116,85% -142,10% -44,62% -23,22% 2,69% -64,82%
53,36% 50,41% 55,03% 53,14% 50,78% 52,54%
1,00% 1,01% 1,61% 1,54% 1,53% 1,34%
96,99% 111,04% 98,98% 95,26% 90,92% 98,64%
77,29% 194,22% 70,59% 80,08% 105,96% 105,63%
73,55% 188,10% 66,12% 75,42% 100,56% 100,75%
33.323.545,91 €-       83.768.122,14 €         52.173.747,27 €-         31.495.327,02 €-         8.508.914,67 €           4.943.116,68 €-           
35.997.403,29 €       75.825.409,53 €         18.687.274,98 €         10.831.791,39 €         39.616.096,43 €         36.191.595,12 €         
69.320.949,20 €-       7.942.712,61 €           70.861.022,25 €-         42.327.118,41 €-         31.107.181,76 €-         41.134.711,80 €-         
162.733.023,30 €    181.090.951,81 €      205.902.011,72 €      225.019.365,35 €      239.345.495,99 €      202.818.169,63 €      
65,03% 66,17% 60,30% 60,23% 59,60% 62,27%
93.604.086,11 €       104.862.552,55 €      128.649.582,25 €      150.398.409,07 €      159.471.372,47 €      127.397.200,49 €      
0,57% 1,75% -0,60% 3,79% 4,53% 2,01%
45,46% 50,41% 68,78% 77,67% 79,21% 64,31%
2,04% 3,73% 2,11% 6,46% 6,06% 4,08%
91,95% 71,01% 151,55% 35,79% 26,21% 75,30%
8,13% 10,84% 12,20% 7,72% 4,37% 8,65%
10.276.968,46 €       14.318.684,73 €         15.730.013,60 €         11.049.029,81 €         8.010.231,91 €           11.876.985,70 €         










Weight of non current assets
Weight of inventories
Degree coverage of non current assets
Current Ratio









Efficiency of invested capital
Return on Assets
Cost Of Debt












2013 2014 2015 2016 2017 2018
EBIT*(1-t) -  €                            24.145.216,46 €       19.608.574,98 €       19.706.617,85 €       19.805.150,94 €       19.904.176,70 €       
Depreciation -  €                            27.529.869,45 €       36.317.950,84 €       36.499.540,59 €       36.682.038,30 €       -  €                            
Change Working Capital -  €                            28.602.009,58 €       2.900.666,92 €          5.316.838,58 €          5.318.422,77 €          5.320.014,88 €          
Capex -  €                            28.300.000,00 €       27.179.582,65 €       27.315.480,56 €       27.452.057,96 €       -  €                            
FCFF 0 -5.226.924 25.846.276 23.573.839 23.716.709 14.584.162
wacc 5,63% 5,63% 5,63% 5,63% 5,63%
1+wacc 105,63% 105,63% 105,63% 105,63% 105,63%
(1+wacc)^n 105,63% 111,57% 117,84% 5,74%
Discounted Value 319.804.254
Cash and Investments 20.680.683,91        
Other Assets 352.984.837,78      
Other Liabilities 178.282.178,94      
Firm Value 515.187.596
Debt 149.420.741,12      





2013 2014 2015 2016 2017 2018
Net Income 9.605.198,82 €         9.653.224,81 €         9.701.490,94 €         9.749.998,39 €         
Depreciation 36.317.950,84 €       36.499.540,59 €       36.682.038,30 €       -  €                            
Change Working Capital 2.900.666,92 €         5.316.838,58 €         5.318.422,77 €         5.320.014,88 €         
Net Debt 146.246.084,34 €    146.977.314,76 €    147.712.201,34 €    -  €                            
Capex 27.179.582,65 €       27.315.480,56 €       27.452.057,96 €       -  €                            
FCFE 162.088.984,43 €    160.497.761,03 €    161.325.249,84 €    4.429.983,51 €         
(1+Re) 1,09 1,19 1,29
Working Capital 2013 2014 2015 2016 2017 2018
(+) Inventories 7.358.159,58 €              7.709.088,11 €              8.383.771,94 €         8.425.690,80 €         8.467.819,26 €         8.510.158,35 €         
(+) Accounts receivable 50.855.614,86 €           82.372.785,89 €            88.292.009,58 €       93.733.469,63 €       99.177.136,98 €       104.623.022,66 €    
(+) Income Taxes 30.460,81 €                    -  €                                 -  €                            -  €                            -  €                            -  €                            
(+) Receivable operational deferred -  €                                -  €                                 -  €                            -  €                            -  €                            -  €                            
(-) Accounts payable 23.618.889,06 €           28.173.687,22 €            32.286.342,54 €       32.447.774,25 €       32.610.013,12 €       32.773.063,19 €       
(-) Payable operational deferred -  €                                -  €                                 -  €                            -  €                            -  €                            -  €                            
(-) Taxes payable 2.729.846,35 €              1.441.138,17 €              1.021.723,46 €         1.026.832,07 €         1.031.966,24 €         1.037.126,07 €         
Net working Capital 31.865.039,03 €           60.467.048,61 €            63.367.715,53 €       68.684.554,11 €       74.002.976,88 €       79.322.991,76 €       
Change Working Capital 28.602.009,58 €            2.900.666,92 €         5.316.838,58 €         5.318.422,77 €         5.320.014,88 €         
Value of Operations Explicit 408.711.583,55 €         
Value of Operations Perpetuity 40.523.349,04 €            
Minority -  €                                 
Equity Value 449.234.932,59 €         
Shares 95.542.254,00 €            
Price Target 4,70 €                               
